BlackRock Amends Corcept Therapeutics Stake, Signals Continued Confidence
Ticker: CORT · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1088856
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still holds Corcept stock, a good sign for investors.**
AI Summary
BlackRock, Inc. filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Common Stock in CORCEPT THERAPEUTICS INCORPORATED as of December 31, 2023. This filing is an amendment (Amendment No: 2) to a previous filing, showing BlackRock continues to hold a significant, though passive, stake in Corcept Therapeutics. This matters to investors because BlackRock is a major institutional investor, and its continued holding signals confidence in the company's long-term prospects, potentially influencing other investors.
Why It Matters
BlackRock's continued, passive ownership in Corcept Therapeutics suggests institutional confidence, which can be a positive signal for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing indicates a passive, institutional holding by BlackRock, which generally poses low risk to the company's operations or stock price.
Analyst Insight
Investors should view BlackRock's continued passive holding as a sign of stability rather than an immediate catalyst. It suggests BlackRock sees long-term value in Corcept Therapeutics, but doesn't indicate any aggressive moves or changes in strategy.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- CORCEPT THERAPEUTICS INCORPORATED (company) — the issuer of the securities
- December 31, 2023 (date) — the date of the event requiring the filing
- January 22, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- BlackRock will maintain its passive stake in Corcept Therapeutics for the foreseeable future. (BlackRock, Inc.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment (Amendment No: 2) to a Schedule 13G filing under the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., identified by CIK 0001364742.
What company's securities are being reported on?
The securities being reported on are Common Stock of CORCEPT THERAPEUTICS INCORPORATED, identified by CIK 0001088856.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding CORCEPT THERAPEUTICS INC (CORT).